Advertisement

Topics

Weekly Investment Analysts' Ratings Changes for BioCryst Pharmaceuticals

13:05 EDT 21 Aug 2017 | Topix

8/10/2017 - BioCryst Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. According to Zacks, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections.

Original Article: Weekly Investment Analysts' Ratings Changes for BioCryst Pharmaceuticals

NEXT ARTICLE

More From BioPortfolio on "Weekly Investment Analysts' Ratings Changes for BioCryst Pharmaceuticals"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...